Compare Intuit Inc. (INTU) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs Twist Bioscience Corp — how do they compare? Intuit Inc. trades at $303.5 (market cap $81.21B), while Twist Bioscience Corp trades at $154.45 (market cap $10.08B). The key difference: Intuit Inc. is far larger — about 8.1× Twist Bioscience Corp's market cap, and Intuit Inc. pays a 1.82% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuit Inc. for 66 Days and Twist Bioscience Corp for 27 Days on average.
| INTU | TWST | |
|---|---|---|
Market Cap | $81.21B | $10.08B |
Volume | 5,165,806 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $683.39 | $205.00 |
52-Week Low | $255.07 | $25.45 |
Typical Hold Time | 66 Days | 27 Days |
Enterprise Value | $82.43B | $10.01B |
Dividend Yield | 1.82% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $303.88, up 4.85% today, with strong fundamental performance including 21.3% net income margin and consistent earnings beats. The stock shows bullish technical momentum with resistance at $308 and support at $293. Recent financials reveal robust revenue growth from $18.8B in 2025 to projected $21.4B in 2026, though legal challenges from class action lawsuits present near-term headwinds.
Outlook remains positive with analyst consensus target of $379.68 (25% upside), driven by AI integration and QuickBooks monetization. Key risks include litigation overhang and competitive pressures in financial software. Institutional sentiment leans bullish with 60% buy ratings, supporting long-term growth trajectory despite technical overbought signals.
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
